Related Experiment Videos
Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular
1Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA.
Insights
Despite strong evidence for cardiovascular disease prevention drugs, patient uptake is low due to various barriers. Further research is needed on optimal intervention combinations and factors limiting real-world effectiveness.
Area of Science:
- Cardiovascular Disease Prevention
- Pharmacologic Interventions
- Evidence-Based Medicine
Background:
- Numerous pharmacologic interventions are recommended for cardiovascular disease (CVD) prevention based on randomized controlled trials.
- These include antihypertensives, lipid-lowering agents, antiplatelets, anticoagulants, estrogen therapy, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors.
Purpose of the Study:
- To highlight the discrepancy between proven efficacy of CVD pharmacologic interventions and their low patient utilization.
- To identify potential barriers to treatment adherence at patient, provider, and institutional levels.
- To underscore the need for research into optimal intervention strategies and factors affecting real-world effectiveness.
Main Methods:
- Review of evidence from randomized controlled trials (RCTs) for pharmacologic CVD prevention.
- Analysis of factors contributing to suboptimal treatment rates.
- Identification of research gaps in optimizing intervention combinations and understanding effectiveness limitations.
Main Results:
- Despite strong evidence and clinical guidelines, a low proportion of patients receive recommended pharmacologic CVD prevention.
- Barriers exist at patient, healthcare provider, and healthcare institution levels.
- Optimal combinations of behavioral and pharmacologic interventions for maximal risk reduction remain unclear.
Conclusions:
- Significant gaps exist between the efficacy of CVD pharmacologic interventions demonstrated in trials and their actual clinical application.
- Addressing patient, provider, and systemic barriers is crucial for improving CVD prevention rates.
- Further epidemiologic and behavioral research is essential to optimize intervention strategies and understand factors limiting real-world effectiveness.
Abstract:
A number of pharmacologic interventions are now recommended for the prevention of cardiovascular disease, based on the results of randomized controlled trials. These include antihypertensive drugs, lipid-lowering agents, antiplatelet and anticoagulant drugs, estrogen replacement therapy, beta-blockers, and angiotensin converting enzyme (ACE) inhibitors. It is likely that additional pharmacologic interactions will soon be proven efficacious. Despite the strength of this evidence and the development of clinical guidelines incorporating their use, a surprisingly low proportion of patients are actively treated with these agents. There may be a variety of explanations for this, including barriers at the level of the patient, health care provider, and health care institution. Finally, a number of questions remain as to the optimal combination of interventions, both behavioral and pharmacologic, which will yield maximal reduction in risk. The description of factors which reduce the effectiveness of pharmacologic interventions below the efficacy demonstrated in randomized clinical trials should be a fertile area for epidemiologic and behavioral research.